Combined oral contraceptives (COCs) have been shaped for sixty years by one adverse event: venous thromboembolism. A clinical review of how COC regimens and their component hormones have evolved argues that the natural-oestrogen formulations now available carry a better safety profile while holding contraceptive efficacy, and that they should probably be the first choice for a woman starting the pill for the first time.
That is a shift in the default rather than a new warning about the old pills. Most prescribers reach for a familiar ethinyl-oestradiol preparation because it is cheap, stocked and well understood, and for a woman already established on one with no problems there is nothing here that says to change her. The argument is about the new start, where the baseline thrombotic risk is highest in the first months and where the choice is genuinely open.
The practical consequence is that the oestrogen in the formulation, not just the progestin, deserves a moment's thought at the point of prescribing. Availability is the limiting factor rather than the evidence: which natural-oestrogen preparations are actually on the shelf in India varies, and the review does not address the Indian market, so check your own formulary before counselling a woman towards one.
- Ask about personal and first-degree family history of unprovoked venous thromboembolism before any first COC prescription.
- Record smoking status and age together — the interaction, not either alone, is what drives the contraindication.
- Note which oestrogen as well as which progestin you have prescribed, so a later switch is informed.
- Check baseline blood pressure and repeat it at the first follow-up.
- Confirm local availability and cost before recommending a natural-oestrogen preparation to a woman who will be paying for it.
Why it matters
The first pill you reach for is a habit rather than a decision in most consultations, and this argues the habit is now the wrong default.
Don't overread it
This is a narrative clinical review, not a randomised comparison — no trial has been reported here showing fewer thrombotic events with a natural-oestrogen pill.
The statistics, in plain English
This review does not report a comparative event rate, so there is no number here to quote to a patient. The claim is that natural-oestrogen COCs carry an improved safety profile with maintained efficacy — a directional statement from expert synthesis, not a measured risk difference from a head-to-head trial.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for obstetrics & gynaecology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free